Executive Vice President, Strategy and Innovation · Xenon Pharmaceuticals Inc. (XENE)

Robin Sherrington

FY2023 is the first fiscal year CompBrief holds for Robin Sherrington as a named executive officer of Xenon Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,373,432

Salary $410,552Stock awards $0

5th of 6 named executive officers at Xenon Pharmaceuticals by FY2023 total.

6 named officers on file for Xenon Pharmaceuticals, FY2023

Robin Sherrington’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • XENE’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xenon Pharmaceuticals’s whole pay program stands against its peers

  • Xenon Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XENE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Robin Sherrington’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robin Sherrington compensation by year

Xenon Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Xenon Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$410,552
Bonus$0
Stock awards$0
Option awards$1,786,404
Non-equity incentive$147,799
Pension and deferred compensation$0
All other$28,677
Total$2,373,432

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xenon Pharmaceuticals Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049198, and prior-year filings.

How this page was built: the Xenon Pharmaceuticals Inc. filed document, accession 0000950170-24-049198. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option16,250—$20.55
Option37,500—$30.01
Option75,000—$34.18

Per the Outstanding Equity Awards at Fiscal Year-End table in Xenon Pharmaceuticals Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Xenon Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Ian MortimerPresident and Chief Executive Officer$10,117,829
Christopher KenneyChief Medical Officer$3,578,066
Sherry AulinChief Financial Officer$3,523,045
Christopher Von SeggernChief Commercial Officer$2,764,805
Robin Sherrington · this pageExecutive Vice President, Strategy and Innovation$2,373,432
Andrea DiFabioChief Legal Officer and Corporate Secretary$1,721,162

The full Xenon Pharmaceuticals compensation record

free company brief

This page is one person within Xenon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xenon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robin Sherrington's compensation dossier · One-time report. No refunds.